Hutch News

Hutch News

Stories tagged 'aacr 2018'

Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal

T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers

April 16, 2018 | By Rachel Tompa / Fred Hutch News Service

In an effort to improve the efficacy of immunotherapy for solid tumors, Fred Hutch researchers have engineered a new type of protein that can rewire a 'kill switch' to stimulate T cells' activity instead.

View story >


How does leukemia escape from immunotherapy?

New tech enables deep dive into mysterious results, sets stage for future improvements

April 16, 2018 | By Susan Keown / Fred Hutch News Service

“We don’t stop asking what we can do better”: Fred Hutch researchers delve into failures to learn how to improve an experimental cancer immunotherapy.

View story >


Should prostate cancer screening be different for black men?

New study confirms prostate cancer is more common and more deadly in African-Americans

April 23, 2017 | By Linda Carroll for Fred Hutch News Service

Newly published research from Fred Hutch shows black men may be at heightened risk not only of developing prostate cancer but also of having a more aggressive form at a younger age.

View story >


Immunotherapy for ovarian cancer shows promise in mouse model, but hurdles remain

‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors

April 4, 2017 | By Rachel Tompa / Fred Hutch News Service

A major roadblock to adopting T-cell therapy to solid tumors is what’s known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor. Fred Hutch researcher Dr. Kristin Anderson and her colleagues in Dr. Phil Greenberg's lab are working to overcome those barriers.

View story >


Finding ways to deliver on the promise of precision oncology

‘Functional genomics’ method aims to marry three powerful techniques to speed personalized cancer treatments to patients

March 31, 2017 | By Rachel Tompa / Fred Hutch News Service

Dr. Christopher Kemp is confident that the answer to personalized cancer treatment is written in the molecules inside each patient’s tumor, we just need to figure out how to separate the wheat from the chaff.

View story >


Immunotherapy shows promise in preventing leukemia relapse

Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years

Dec. 5, 2016 | By Susan Keown / Fred Hutch News Service

For patients with high-risk acute myeloid leukemia, relapse after bone marrow transplant signals a low chance of survival. But results from a small trial of genetically engineered immune cells show promise for keeping these patients out of danger: Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.